Compare Crispr Therapeutics AG (CRSP) vs Rush Street Interactive Inc (RSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Rush Street Interactive Inc — how do they compare? Crispr Therapeutics AG trades at $53.55 (market cap $4.88B), while Rush Street Interactive Inc trades at $18.9 (market cap $2.35B). The key difference: Crispr Therapeutics AG is far larger — about 2.1× Rush Street Interactive Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Rush Street Interactive Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Rush Street Interactive Inc for 13 Days on average.
| CRSP | RSI | |
|---|---|---|
Market Cap | $4.88B | $2.35B |
Volume | 2,861,747 | 2,219,374 |
Sector | Health | Consumer Cyclical |
52-Week High | $74.92 | $34.52 |
52-Week Low | $44.34 | $15.89 |
Typical Hold Time | 77 Days | 13 Days |
Enterprise Value | $3.30B | $2.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
RSI (Rush Street Interactive) trades at $18.90, down 6.62% recently, with a bearish technical signal from moving averages. The company shows strong revenue growth from $1.13B in 2025 to $1.4B in 2026, though net income margin compressed to 2.33%. Recent Q2 2026 earnings beat expectations with EPS of $0.15 versus $0.1499 expected. Analyst consensus remains strongly bullish with 10 buy ratings and a $34.88 price target, representing 85% upside potential from current levels.
The stock presents significant upside based on analyst targets but faces execution risks amid competitive online gaming markets. High P/E ratio of 65.55 suggests premium valuation requiring sustained growth. Institutional interest remains strong with BlackRock's $448M investment in Q2 2026. Near-term performance hinges on Q3 earnings delivery and sports betting market expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →
